Clinical observation of basiliximab plus single steroid induced immunotherapy during pediatric liver transplantation
10.3760/cma.j.cn421203-20201213-00421
- VernacularTitle:巴利昔单抗联合减量糖皮质激素诱导免疫方案在儿童肝移植的临床应用
- Author:
Chong DONG
1
;
Chao SUN
;
Jing CHEN
;
Weiping ZHENG
;
Hong QING
;
Kai WANG
;
Yang YANG
;
Fubo ZHANG
;
Chao HAN
;
Wei GAO
Author Information
1. 天津市第一中心医院儿童器官移植科 天津市器官移植临床医学研究中心 天津市器官移植重点实验室 300192
- Keywords:
Liver transplantation;
Child;
Basiliximab;
Glucocorticoid;
Rejection
- From:
Chinese Journal of Organ Transplantation
2021;42(3):136-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of basiliximab plus single steroid induced immunotherapy during donor-recipient ABO-compatible pediatric liver transplantation(LT).Methods:From January 1, 2019 to January 19, 2020, a total of 150 children of donor-recipient ABO-compatible LT were randomly divided into basiliximab group(basiliximab plus single steroid induction and postoperative immunosuppression with tacrolimus alone)and steroid group(conventional dose of steroid induction plus postoperative immunosuppression with tacrolimus and steroid). Clinical characteristics, survival rate of recipients and liver allografts, rejection rate and infection rate were observed.Results:The median follow-up time was 9.2(0.7~15.5)months.No significant inter-group differences existed in survival rate of recipients/grafts or the incidence of acute rejection, early postoperative pulmonary infection, cytomegalovirus and Epstein Barr virus infection. However, in 56 living donor LT, acute rejection(6cases, 10.7%)occurred in basiliximab group versus(12cases, 25.5%)in steroid group. During living donor LT, the incidence of acute rejection declined markedly in bsiliximab group as compared with steroid group( P=0.043). Conclusions:Both safe and effective for donor-recipient ABO-compatible pediatric LT, basiliximab plus single steroid induced immunotherapy can significantly lower the occurrences of acute rejection during living donor LT.
